OxStem, acting as a parent holding company, will spin-out and fund the development over time of a series of daughter companies. Each daughter company (or “Stem”) is focused on a large unmet therapeutic need within different organ systems (e.g. Dementia / Alzheimer’s in the CNS, or Macular Degeneration within the Eye).

At present we have established six Stem companies: OxStem Oncology, OxStem Neuro, OxStem Ocular, OxStem Cardio, OxStem Beta and OxStem Immuno.

Read more